{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T22:04:04Z","timestamp":1773353044674,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["R01HL148080"],"award-info":[{"award-number":["R01HL148080"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL148080"],"award-info":[{"award-number":["R01HL148080"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association Inc","doi-asserted-by":"publisher","award":["TPA1075016"],"award-info":[{"award-number":["TPA1075016"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jpet.2025.103600","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T06:20:00Z","timestamp":1746771600000},"page":"103600","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Death receptor 5 agonists mitigate cardiac pathology in a chronic isoproterenol-induced cardiac remodeling and dysfunction"],"prefix":"10.1016","volume":"392","author":[{"given":"Miles A.","family":"Tanner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina","family":"Dougherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurel A.","family":"Grisanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2025.103600_bib1","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart disease and stroke statistics-2017 Update: a report from the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jpet.2025.103600_bib2","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1161\/ATVBAHA.111.224915","article-title":"Mechanisms of cell death in heart disease","volume":"32","author":"Konstantinidis","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jpet.2025.103600_bib3","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1161\/CIRCRESAHA.115.305765","article-title":"Recent developments in heart failure","volume":"117","author":"Dassanayaka","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.jpet.2025.103600_bib4","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1161\/CIRCULATIONAHA.116.023518","article-title":"The future of heart failure diagnosis, therapy, and management","volume":"133","author":"Udelson","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jpet.2025.103600_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2011.130","article-title":"Cardiomyocyte death: mechanisms and translational implications","volume":"2","author":"Chiong","year":"2011","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jpet.2025.103600_bib6","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1172\/JCI62837","article-title":"Potential of gene therapy as a treatment for heart failure","volume":"123","author":"Hajjar","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jpet.2025.103600_bib7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cardiores.2005.04.012","article-title":"Myocyte apoptosis in heart failure","volume":"67","author":"van Empel","year":"2005","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jpet.2025.103600_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1023\/A:1011449708842","article-title":"Recent insights into the role of tumor necrosis factor in the failing heart","volume":"6","author":"Mann","year":"2001","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jpet.2025.103600_bib9","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1536\/jhj.44.833","article-title":"Enhanced expression of the apoptosis inducing ligand TRAIL in mononuclear cells after myocardial infarction","volume":"44","author":"Nakajima","year":"2003","journal-title":"Jpn Heart J"},{"key":"10.1016\/j.jpet.2025.103600_bib10","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1369\/jhc.3A6112.2004","article-title":"Tissue distribution of the death ligand TRAIL and its receptors","volume":"52","author":"Spierings","year":"2004","journal-title":"J Histochem Cytochem"},{"key":"10.1016\/j.jpet.2025.103600_bib11","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.277.5327.815","article-title":"An antagonist decoy receptor and a death domain-containing receptor for TRAIL","volume":"277","author":"Pan","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.jpet.2025.103600_bib12","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1126\/science.276.5309.111","article-title":"The receptor for the cytotoxic ligand TRAIL","volume":"276","author":"Pan","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.jpet.2025.103600_bib13","doi-asserted-by":"crossref","first-page":"25417","DOI":"10.1074\/jbc.272.41.25417","article-title":"Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL","volume":"272","author":"MacFarlane","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jpet.2025.103600_bib14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1044-579X(02)00131-1","article-title":"Cell surface death receptor signaling in normal and cancer cells","volume":"13","author":"Ozoren","year":"2003","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.jpet.2025.103600_bib15","first-page":"2770","article-title":"Molecular cloning and functional analysis of the mouse homologue of the KILLER\/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor","volume":"59","author":"Wu","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.jpet.2025.103600_bib16","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood-2003-06-2137","article-title":"TRAIL regulates normal erythroid maturation through an ERK-dependent pathway","volume":"103","author":"Secchiero","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jpet.2025.103600_bib17","article-title":"Activation of the Akt survival pathway contributes to TRAIL resistance in cancer cells","volume":"5","author":"Xu","year":"2010","journal-title":"PLOS One"},{"key":"10.1016\/j.jpet.2025.103600_bib18","doi-asserted-by":"crossref","first-page":"40599","DOI":"10.1074\/jbc.M509560200","article-title":"Molecular determinants of kinase pathway activation by Apo2 ligand\/tumor necrosis factor-related apoptosis-inducing ligand","volume":"280","author":"Varfolomeev","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jpet.2025.103600_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yjmcc.2019.08.011","article-title":"Death receptor 5 contributes to cardiomyocyte hypertrophy through epidermal growth factor receptor transactivation","volume":"136","author":"Tanner","year":"2019","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jpet.2025.103600_bib20","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nchembio.1153","article-title":"Small-molecule activation of the TRAIL receptor DR5 in human cancer cells","volume":"9","author":"Wang","year":"2013","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.jpet.2025.103600_bib21","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1161\/01.RES.0000077012.11088.BC","article-title":"Phenotyping hypertrophy: eschew obfuscation","volume":"92","author":"Dorn","year":"2003","journal-title":"Circ Res"},{"key":"10.1016\/j.jpet.2025.103600_bib22","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.699102","article-title":"A dual role for death receptor 5 in regulating cardiac fibroblast function","volume":"8","author":"Tanner","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jpet.2025.103600_bib23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/ejhf.980","article-title":"Circulating proteins as predictors of incident heart failure in the elderly","volume":"20","author":"Stenemo","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jpet.2025.103600_bib24","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ebiom.2017.11.023","article-title":"Elevated markers of death receptor-activated apoptosis are associated with increased risk for development of diabetes and cardiovascular disease","volume":"26","author":"Mattisson","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jpet.2025.103600_bib25","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1177\/2047487317725017","article-title":"GDF-15 and TRAIL-R2 are powerful predictors of long-term mortality in patients with acute myocardial infarction","volume":"24","author":"Skau","year":"2017","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jpet.2025.103600_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCGENETICS.116.001633","article-title":"Inflammatory biomarkers predict heart failure severity and prognosis in patients with heart failure with preserved ejection fraction: a holistic proteomic approach","volume":"10","author":"Hage","year":"2017","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.jpet.2025.103600_bib27","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/j.bbrc.2005.10.136","article-title":"TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy","volume":"338","author":"Schoppet","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jpet.2025.103600_bib28","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/eurheartj\/ehp004","article-title":"Prognostic value of apoptosis markers in advanced heart failure patients","volume":"30","author":"Niessner","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jpet.2025.103600_bib29","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1128\/MCB.25.5.2000-2013.2005","article-title":"DR5 knockout mice are compromised in radiation-induced apoptosis","volume":"25","author":"Finnberg","year":"2005","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.jpet.2025.103600_bib30","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.7150\/thno.26619","article-title":"Pepducin-mediated cardioprotection via \u03b2-arrestin-biased \u03b22-adrenergic receptor-specific signaling","volume":"8","author":"Grisanti","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.jpet.2025.103600_bib31","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1161\/CIRCRESAHA.109.201418","article-title":"Loss of plakophilin-2 expression leads to decreased sodium current and slower conduction velocity in cultured cardiac myocytes","volume":"105","author":"Sato","year":"2009","journal-title":"Circ Res"},{"key":"10.1016\/j.jpet.2025.103600_bib32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.yjmcc.2014.02.009","article-title":"\u03b2-adrenergic receptor-mediated transactivation of epidermal growth factor receptor decreases cardiomyocyte apoptosis through differential subcellular activation of ERK1\/2 and Akt","volume":"72","author":"Grisanti","year":"2014","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.jpet.2025.103600_bib33","first-page":"97","article-title":"The athlete's heart vs. the failing heart: can signaling explain the two distinct outcomes?","volume":"26","author":"Weeks","year":"2011","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.jpet.2025.103600_bib34","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fphar.2015.00149","article-title":"Extracellular signal-regulated kinases 1\/2 as regulators of cardiac hypertrophy","volume":"6","author":"Mutlak","year":"2015","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jpet.2025.103600_bib35","doi-asserted-by":"crossref","first-page":"H633","DOI":"10.1152\/ajpheart.00243.2021","article-title":"Immune cell beta(2)-adrenergic receptors contribute to the development of heart failure","volume":"321","author":"Tanner","year":"2021","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jpet.2025.103600_bib36","doi-asserted-by":"crossref","first-page":"H316","DOI":"10.1152\/ajpheart.00635.2014","article-title":"Temporal and gefitinib-sensitive regulation of cardiac cytokine expression via chronic beta-adrenergic receptor stimulation","volume":"308","author":"Grisanti","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.jpet.2025.103600_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2020.529075","article-title":"The dynamic interplay between cardiac inflammation and fibrosis","volume":"11","author":"Thomas","year":"2020","journal-title":"Front Physiol"},{"key":"10.1016\/j.jpet.2025.103600_bib38","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1161\/01.CIR.98.13.1329","article-title":"Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the beta-adrenergic pathway","volume":"98","author":"Communal","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jpet.2025.103600_bib39","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1161\/01.CIR.102.3.344","article-title":"Beta-adrenergic receptor subtypes differentially affect apoptosis in adult rat ventricular myocytes","volume":"102","author":"Zaugg","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jpet.2025.103600_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1083\/jcb.124.1.1","article-title":"Bcl-2 and the regulation of programmed cell death","volume":"124","author":"Reed","year":"1994","journal-title":"J Cell Biol"},{"key":"10.1016\/j.jpet.2025.103600_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1256852","article-title":"TRAIL and its receptors in cardiac diseases","volume":"14","author":"Grisanti","year":"2023","journal-title":"Front Physiol"},{"key":"10.1016\/j.jpet.2025.103600_bib42","first-page":"346","article-title":"ERK1\/2: an integrator of signals that alters cardiac homeostasis and growth","volume":"10","author":"Gilbert","year":"2021","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.jpet.2025.103600_bib43","doi-asserted-by":"crossref","first-page":"8507","DOI":"10.3390\/ijms21228507","article-title":"\u03b22-adrenergic receptors increase cardiac fibroblast proliferation through the Galphas\/ERK1\/2-dependent secretion of interleukin-6","volume":"21","author":"Tanner","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jpet.2025.103600_bib44","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1172\/JCI6926","article-title":"Safety and antitumor activity of recombinant soluble Apo2 ligand","volume":"104","author":"Ashkenazi","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jpet.2025.103600_bib45","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/5517","article-title":"Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo","volume":"5","author":"Walczak","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.jpet.2025.103600_bib46","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1200\/JCO.2009.25.1991","article-title":"Phase I dose-escalation study of recombinant human Apo2L\/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer","volume":"28","author":"Herbst","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpet.2025.103600_bib47","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.2009.25.4847","article-title":"Phase 1b study of dulanermin (recombinant human Apo2L\/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer","volume":"28","author":"Soria","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jpet.2025.103600_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2024.1384795","article-title":"Targeting Death Receptor 5 (DR5) for the imaging and treatment of primary bone and soft tissue tumors: an update of the literature","volume":"11","author":"Gamie","year":"2024","journal-title":"Front Mol Biosci"},{"key":"10.1016\/j.jpet.2025.103600_bib49","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1038\/nrc2465","article-title":"The TRAIL apoptotic pathway in cancer onset, progression and therapy","volume":"8","author":"Johnstone","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jpet.2025.103600_bib50","doi-asserted-by":"crossref","first-page":"16254","DOI":"10.1073\/pnas.0806849105","article-title":"Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response","volume":"105","author":"Stagg","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jpet.2025.103600_bib51","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrc.2017.28","article-title":"Exploring the TRAILs less travelled: TRAIL in cancer biology and therapy","volume":"17","author":"von Karstedt","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jpet.2025.103600_bib52","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1161\/HYPERTENSIONAHA.123.22329","article-title":"Tail-cuff versus radiotelemetry to measure blood pressure in mice and rats","volume":"81","author":"Harrison","year":"2024","journal-title":"Hypertension"},{"key":"10.1016\/j.jpet.2025.103600_bib53","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/j.1440-1681.2009.05243.x","article-title":"Downregulation of survival signalling pathways and increased apoptosis in the transition of pressure overload-induced cardiac hypertrophy to heart failure","volume":"36","author":"Li","year":"2009","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.jpet.2025.103600_bib54","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/01.CIR.0000138190.50127.6A","article-title":"Raf-1 kinase is required for cardiac hypertrophy and cardiomyocyte survival in response to pressure overload","volume":"110","author":"Harris","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jpet.2025.103600_bib55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188471","article-title":"Shift toward greater pathologic post-myocardial infarction remodeling with loss of the adaptive hypertrophic signaling of alpha1 adrenergic receptors in mice","volume":"12","author":"Yeh","year":"2017","journal-title":"PLOS One"},{"key":"10.1016\/j.jpet.2025.103600_bib56","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201745235","article-title":"Phosphorylation switches Bax from promoting to inhibiting apoptosis thereby increasing drug resistance","volume":"19","author":"Kale","year":"2018","journal-title":"EMBO Rep"},{"key":"10.1016\/j.jpet.2025.103600_bib57","doi-asserted-by":"crossref","first-page":"31108","DOI":"10.1074\/jbc.274.43.31108","article-title":"Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK\/Erk kinase","volume":"274","author":"Scheid","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jpet.2025.103600_bib58","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1126\/science.286.5443.1358","article-title":"Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms","volume":"286","author":"Bonni","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.jpet.2025.103600_bib59","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2567.2009.03058.x","article-title":"Following TRAIL\u2019s path in the immune system","volume":"127","author":"Falschlehner","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.jpet.2025.103600_bib60","doi-asserted-by":"crossref","DOI":"10.1007\/s10557-024-07591-z","article-title":"Blocking the TRAIL-DR5 pathway reduces cardiac ischemia-reperfusion injury by decreasing neutrophil infiltration and neutrophil extracellular traps formation","author":"Wang","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jpet.2025.103600_bib61","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw3172","article-title":"Blocking the death checkpoint protein TRAIL improves cardiac function after myocardial infarction in monkeys, pigs, and rats","volume":"12","author":"Wang","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jpet.2025.103600_bib62","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s00380-022-02197-7","article-title":"TRAIL inhibition by soluble death receptor 5 protects against acute myocardial infarction in rats","volume":"38","author":"Wang","year":"2023","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jpet.2025.103600_bib63","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0008-6363(97)00212-5","article-title":"Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system","volume":"37","author":"Grimm","year":"1998","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jpet.2025.103600_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2017.423","article-title":"Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells","volume":"8","author":"Shlyakhtina","year":"2017","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.jpet.2025.103600_bib65","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/sj.cgt.7700792","article-title":"Mechanisms of resistance to TRAIL-induced apoptosis in cancer","volume":"12","author":"Zhang","year":"2005","journal-title":"Cancer Gene Ther"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525398137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525398137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T10:17:34Z","timestamp":1751019454000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525398137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":65,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0022356525398137"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103600","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Death receptor 5 agonists mitigate cardiac pathology in a chronic isoproterenol-induced cardiac remodeling and dysfunction","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103600","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103600"}}